The burgeoning hype around GLP-1 weight loss drugs as a panacea for the obesity pandemic has propelled Eli Lilly and Company (LLY) shares to previously unimaginable zeniths while leaving Pfizer (PFE), a former darling of the pharma world, in the proverbial dust bowl. One of the most eye-opening charts you'll see right now, this shows Eli Lilly's $LLY price to sales ratio vs Pfizer's $PFE price to sales ratio over time. Lilly is up to 18x versus Pfizer's 2x. The two were roughly the same in early 2021. pic.twitter.com/g9ycAWBEiM — Bespoke (@bespokeinvest) January 19, 2024 As is shown in the […]
Read full article at https://wccftech.com/want-to-find-out-the-level-of-hype-surrounding-the-glp-1-weight-loss-drugs-just-look-at-this-comparison-between-eli-lilly-and-company-lly-and-pfizer/
WccftechContinue reading/original-link]